

References for Module 5

1. Small Intestinal Bacterial Overgrowth A Comprehensive Review, Andrew C. Dukowicz et al, *Gastroenterol Hepatol* (N Y). 2007 Feb; 3(2): 112–122.
2. Corraza GR, Menozzi MG, Strocchi A, et al. The diagnosis of small bowel bacterial overgrowth: reliability of jejunal culture and inadequacy of breath hydrogen testing. *Gastroenterology*. 1990;98:302–309.
3. Issacs PE, Kim YS. Blind loop syndrome and small bowel bacterial contamination. *Clin Gastroenterol*. 1983;12:395–414.
4. Bouhnik Y, Alain S, Attar A, et al. Bacterial populations contaminating the upper gut in patients with small intestinal bacterial overgrowth syndrome. *Am J Gastroenterol*. 1999;94:1327–1331.
5. Parlesak A, Klein B, Schecher K, et al. Prevalence of small bowel bacterial overgrowth and its association with nutrition intake in nonhospitalized older adults. *J Am Geriatr Soc*. 2003;51:768–773.
6. Mitsui T, Kagami H, Kinomoto H, et al. Small bowel bacterial overgrowth and rice malabsorption in healthy and physically disabled older adults. *J Hum Nutr Dietet*. 2003;16:119–122.
7. Teo M, Chung S, Chitti L, et al. Small bowel bacterial overgrowth is a common cause of chronic diarrhea. *J Gastro Hepatol*. 2004;19:904–909.
8. The role of lactobacillus probiotics in the treatment or prevention of urogenital infections--a systematic review. Abad CL1, Safdar N. *J Chemother*. 2009 Jun;21(3):243-52.
9. Lewis SJ, Potts LF, Malhotra R, et al. Small bowel bacterial overgrowth in subjects living in residential care homes. *Age Ageing*. 1999;28:181–185.
10. Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: a double-blind, randomized, placebo-controlled study. *Am J Gastroenterol*. 2003;98:412–419.
11. Riordan SM, McIver CJ, Wakefield D, et al. Small intestinal mucosal immunity and morphometry in luminal overgrowth of indigenous gut flora. *Am J Gastroenterol*. 2001;96:494–500.
12. Haboubi NY, Lee GS, Montgomery RD. Duodenal mucosal morphometry of elderly patients with small intestinal bacterial overgrowth: Response to antibiotics treatment. *Age Ageing*. 1991;20:29–32. [
13. Saltzman JR, Kowdley KV, Pedrosa MC, et al. Bacterial overgrowth without clinical malabsorption in elderly hypochlorhydric subjects. *Gastroenterology*. 1994;106:615–623.
14. Husebye E, Skar V, Hoverstad T, et al. Fasting hypochlorhydria with gram positive gastric flora is highly prevalent in healthy old people. *Gut*. 1992;33:1331–1337.

15. Iivonen MK, Ahola TO, Matikainen MJ. Bacterial overgrowth, intestinal transit, and nutrition after total gastrectomy. *Scand J Gastroenterol.* 1998;33:63–70.
16. Brandi G, Biavati B, Calabrese C, et al. Urease-positive bacteria other than *Helicobacter pylori* in human gastric juice and mucosa. *Am J Gastroenterol.* 2006;101:1756–1761
17. Shindo K, Fukumura M. Effect of H₂-receptor antagonists on bile acid metabolism. *J Invest Med.* 1995;43:170–177.
18. Thorens J, Froehlich F, Schwizer W, et al. Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study. *Gut.* 1996;39:54–5
19. In vitro antimicrobial properties of coconut oil on *Candida* species in Ibadan, Nigeria. Ogbolu DO1, Oni AA, Daini OA, Oloko AP. *J Med Food.* 2007 Jun;10(2):384–7.
20. Antifungal activity of the essential oil of *Melaleuca alternifolia* (tea tree oil) against pathogenic fungi in vitro. Nenoff P1, Hausteil, *Skin Pharmacol.* 1996;9(6):388–94.
21. Resistance of *Candida* Species to Fluconazole, John H. Rex,^{1,2*} M. G. Rinaldi,³ And M. A. Pfaller⁴, *Antimicrobial Agents And Chemotherapy*, Jan. 1995, p. 1–8 Vol. 39, No. 1 0066–4804/95
22. Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity, and cancer. Fasano A1, *Physiol Rev.* 2011 Jan;91(1):151–75.
23. Tight Junctions, Intestinal Permeability, and Autoimmunity Celiac Disease and Type 1 Diabetes Paradigms, Jeroen Visser, *Ann N Y Acad Sci.* PMC 2010 Jun 16.
24. Leading article, Intestinal zonulin: open sesame, A FASANO, *Gut* 2001;49:159–162
25. Lactobacillus GG restoration of the gliadin induced epithelial barrier disruption: the role of cellular polyamines. Orlando A, Linsalata M, Notarnicola M, Tutino V, Russo F1. *BMC Microbiol.* 2014 Jan 31;14:19.
26. Zonulin and Its Regulation of Intestinal Barrier Function: The Biological Door to Inflammation, Autoimmunity, and Cancer, Alessio Fasano, *Physiological Reviews* Published 1 January 2011 Vol. 91 no. 1, 151–175
<http://physrev.physiology.org/content/91/1/151>
27. <http://www.lsgc.org/admin/uploads/Celiac%20beyond%20GFD%20-%20EI%20Sayed.pdf>
28. The effects of perioperative probiotic treatment on serum zonulin concentration and subsequent postoperative infectious complications after colorectal cancer surgery: a double-center and double-blind randomized clinical trial^{1–4}, Zhi-Hua Liu et al, *AJCN.* December 12, 2012
29. Inhibition of *Candida albicans* by *Lactobacillus acidophilus*: evidence for the involvement of a peroxidase system. Fitzsimmons N1, Berry DR., *Microbios.* 1994;80(323):125–33.
30. Inhibition of *Candida albicans* by *Lactobacillus acidophilus*. Collins EB, Hardt P, *J Dairy Sci.* 1980 May;63(5):830–2.

31. Current trends in *Candida albicans* research., Datta A1, Ganesan K, Natarajan K. *Adv, Microb Physiol.* 1989;30:53-88.
32. Limited effect of refined carbohydrate dietary supplementation on colonization of the gastrointestinal tract of healthy subjects by *Candida albicans*^{1,2} Michael Weig, Edgar Werner, Matthias Frosch, and Heinrich Kasper, *Am J Clin Nutr* June 1999 **vol. 69 no. 6** 1170-1173
33. Bacteria as the cause of ulcerative colitis, Massimo Campieri, Paolo Gionchetti, *Gut* 2001;48:132-135 <http://gut.bmj.com/content/48/1/132.full>
34. Short-chain fatty acids in ulcerative colitis. Kim YI¹., *Nutr Rev.* 1998 Jan;56(1 Pt 1):17-24
35. A novel probiotic mixture exerts a therapeutic effect on experimental autoimmune encephalomyelitis mediated by IL-10 producing regulatory T cells. Lavasani S1 et al, *PLoS One.* 2010 Feb 2;5(2):e9009.
36. Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls, Jun Chen et al, *Scientific Reports* 6, Article number: 28484 (2016)
37. Dynamics of Gut Microbiota in Autoimmune Lupus, Husen Zhanga et al, *Appl. Environ. Microbiol.* December 2014 vol. 80 no. 24 7551-7560
38. Effects of *Lactobacillus casei* supplementation on disease activity and inflammatory cytokines in rheumatoid arthritis patients: a randomized double-blind clinical trial. Alipour B1 et al, *Int J Rheum Dis.* 2014 Jun;17(5):519-27.
39. Analysis of fecal *Lactobacillus* community structure in patients with early rheumatoid arthritis. Liu X1, Zou Q, Zeng B, Fang Y, Wei H. *Curr Microbiol.* 2013 Aug;67(2):170-6
40. *Lactobacillus helveticus* suppresses experimental rheumatoid arthritis by reducing inflammatory T cell responses, Jung-Eun Kima, *Journal of Functional Foods* Volume 13, March 2015, Pages 350–362
41. The oral and gut microbiomes are perturbed in rheumatoid arthritis and partly normalized after treatment, Xuan Zhang et al, *Nature Medicine* 21, 895–905 (2015)
42. Nutrition Facts in Multiple Sclerosis, Paolo Riccio and Rocco Rossano, *ASN Neuro.* 2015 Jan-Feb; 7(1): 1759091414568185.
43. Engineered Commensal Bacteria Reprogram Intestinal Cells Into Glucose-Responsive Insulin-Secreting Cells for the Treatment of Diabetes, Franklin F. Duan, Joy H. Liu, John C. March, *Diabetes* 2015 Jan; db140635
44. The Dynamics of the Human Infant Gut Microbiome in Development and in Progression toward Type 1 Diabetes, Aleksandar D. Kostic¹ et al, *Cell Host & Microbe*, Volume 17, Issue 2, 11 February 2015, Pages 260–273
45. Highly Efficient Gluten Degradation by Lactobacilli and Fungal Proteases during Food Processing: New Perspectives for Celiac Disease, Carlo G. Rizzello et al, *Appl Environ Microbiol.* 2007 Jul; 73(14): 4499–4507

46. Decrease in lactobacilli in the intestinal microbiota of celiac children with a gluten-free diet, and selection of potentially probiotic strains, Lorenzo Pisarello MJ, Can J Microbiol. 2015 Jan;61(1):32-7
47. Gluten induces coeliac-like disease in sensitised mice involving IgA, CD71 and transglutaminase 2 interactions that are prevented by probiotics. RC, Yiangou M. Lab Invest. 2012 Feb 13. doi: 10.1038/labinvest.2012.13.
48. Unraveling the ties between celiac disease and intestinal microbiota. Sanz Y, De Pama G, Laparra M, Int Rev Immunol. 2011 Aug;30(4):207-18.
49. Probiotics, prebiotics, and synbiotics. de Vrese M, Schrezenmeir J Adv Biochem Eng Biotechnol. 2008;111:1-66.

50. Prophylactic effect of dietary glutamine supplementation on interleukin 8 and tumour necrosis
51. factor α production in trinitrobenzene sulphon 1997;41:487-493
52. The effect of L-glutamine on mucosal healing in experimental colitis is superior to short-chain fatty acids.Kaya E1, Turk J Gastroenterol. 2007 Jun;18(2):89-94
53. Sulphate-reducing bacteria and hydrogen sulphide in the aetiology of ulcerative colitis.Rowan FE1, Br J Surg. 2009 Feb;96(2):151-8
54. Curcumin for inflammatory bowel disease: a review of human studies.Taylor RA, Altern Med Rev. 2011 Jun;16(2):152-6.
55. Dietary Supplementation with Fresh Pineapple Juice Decreases Inflammation and Colonic
56. Neoplasia in IL-10-deficient Mice with Colitis, Laura P. Hale, M.D. Ph.D.,* Maciej Chichlowski, Ph.D., Chau T. Trinh, B.S., and Paula K. Greer et al, Inflamm Bowel Dis. 2010 Dec; 16(12): 2012–2021.
57. Oral butyrate for mildly to moderately active Crohn's disease, Di Sabatino et al, Aliment Pharmacol Ther. 2005 Nov 1;22(9):789-94.
58. Effect of Long-Term Oral Glutamine Supplements on Small Intestinal Permeability in Patients With Crohn's Disease, Elly Den Hond, PhD et al,JPEN J Parenter Enteral Nutr January 1999 vol. 23 no. 1 7-11
59. Combined Glutamine and Arginine Decrease Proinflammatory Cytokine Production by Biopsies
60. from Crohn's Patients in Association with Changes in Nuclear Factor-Kb and p38 Mitogen
61. Activated Protein Kinase Pathways1–3, Stéphane Lecleire, J. Nutr. December 2008 vol. 138 no. 12 2481-2486
62. High-dose oral supplementation of antioxidants and glutamine improves the antioxidant status in patients with Crohn's disease: A pilot study, Cornelia Roggenbuck, Clinical Nutrition Espen.October 2008Volume 3, Issue 5, Pages e246–e253
63. The Role of Klebsiella in Crohn's Disease with a Potential for the Use of Antimicrobial Measures, Taha Rashid, Int J Rheumatol. 2013; 2013: 610393.
64. Resistant starches types 2 and 4 have differential effects on the composition of the fecal microbiota in human subjects. Martínez I, et al, PLoS ONE. 2010;5:e15046
65. Randomized controlled trial: Moxibustion and a Chun-Hui Bao, World J Gastroenterol. 2014 Aug 21; 20(31): 11000–11011.
66. The brain-gut axis in abdominal pain syndromes. Mayer EA1, Tillisch K.Annu Rev Med. 2011;62:381-96.
<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3817711/figure/F3/>
67. The Brain-Gut Axis: From Basic Understanding to Treatment of Irritable Bowel Syndrome and Related Disorders, Michael Camilleri, M.D J Pediatr Gastroenterol Nutr. 2012 Apr; 54(4): 446– 453.
68. Gut/brain axis and the microbiota, Emeran A. Mayer1,2,3, et al, The Journal of Clinical Investigations February 17, 2015

69. The intestinal microbiota affect central levels of brain-derived neurotrophic factor and behavior in mice, Bercik P1 et al, *Gastroenterology*. 2011 Aug;141(2):599-609, 609.e1-3.
70. Gut Vagal Afferents Differentially Modulate Innate Anxiety and Learned Fear, Melanie Klarer1 et al, *The Journal of Neuroscience*, 21 May 2014, 34(21): 7067-7076;
71. Regulation and dysregulation of glutamate transporters. Sattler R1, Rothstein JD., *Handb Exp Pharmacol*. 2006;(175):277-303.
72. Reversal of cognitive decline: A novel therapeutic program , Dale E. Bredesen1, 21 Mary S. Easton Center for Alzheimer's Disease Research, Department of Neurology, University of California, *AGING*, Vol 6, No 9, pp 707-717
73. Amyloid Precursor Protein Mediated Changes in Intestinal Epithelial Phenotype In Vitro, Kendra L. Puig, *PLoS One*. 2015; 10(3): e0119534
74. Migraine Associated with Gastrointestinal Disorders: Review of the Literature and Clinical Implications, Saskia van Hemert et al, *Front Neurol*. 2014; 5: 241.
75. Lipopolysaccharide (Endotoxin)-host defense antibacterial peptides interactions: Role in bacterial resistance and prevention of sepsis, Yosef Rosenfeld et al, *Biochimica et Biophysica Acta (BBA) - Biomembranes*, Volume 1758, Issue 9, September 2006, Pages 1513–1522
76. A rat model of autism induced by a single early prenatal exposure to LPS, T.B. Kirsten et al, *Brain, Behavior, and Immunity*, Volume 26, Supplement 1, September 2012, Pages S4
77. <http://www.microbialinfluence.com/ASD.html>
78. Autism may have link to chemicals made by gut microbes: Mice with altered intestines were less social and more anxious, By Tina Hesman Saey, *Science news*, Vol. 185 No. 1, January 11, 2014,
79. p. 8
80. Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease. Hynd MR1, *Neurochem Int*. 2004 Oct;45(5):583-95.
81. Glutamine Acts as a Neuroprotectant against DNA Damage, Beta-Amyloid and H2O2-Induced Stress Jianmin Chen* et al, *PLoS One*. 2012; 7(3): e3317

